StockNews.AI
ORN
StockNews.AI
3 days

337,000 Orion Corporation A shares converted into B shares

1. 337,000 A shares converted to B shares as per articles of association. 2. Total shares now stand at 141,134,278 post-conversion. 3. Orion specializes in human and veterinary pharmaceuticals, focusing on oncology and pain. 4. 2024 net sales reached EUR 1,542 million, employing 3,700 people globally. 5. The conversion affects voting power but not overall market position significantly.

4m saved
Insight
Article

FAQ

Why Neutral?

Share conversions typically do not significantly alter stock value dynamics. Historical cases, such as stock splits or conversions at other companies, show minimal immediate impact.

How important is it?

Share conversions can affect liquidity and voting power but are often anticipated.

Why Short Term?

Share conversions have immediate register effects but usually don't influence long-term valuation.

Related Companies

N/A
August 20, 2025 02:00 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at 9.00 EEST         337,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 337,000 A shares have been converted into 337,000 B shares. The conversion has been entered into the Trade Register on 20 August 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,971,783 A shares and 109,162,495 B shares. The number of votes of the company's shares is after the conversion 748,598,155. Orion Corporation Liisa Hurme President and CEO     Mikko Kemppainen General Counsel   Contact person:Tuukka Hirvonen, Head of Investor Relations, tel. +358 10 426 2721                                                  Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orionpharma.com Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

Related News